## Francesco Paolo Fiorentino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1219573/publications.pdf

Version: 2024-02-01

20 papers 545 citations

11 h-index 19 g-index

21 all docs

21 docs citations

21 times ranked 1127 citing authors

#	Article	IF	Citations
1	Bromodomain Inhibitor JQ1 Provides Novel Insights and Perspectives in Rhabdomyosarcoma Treatment. International Journal of Molecular Sciences, 2022, 23, 3581.	4.1	4
2	A Micro-Immunotherapy Sequential Medicine MIM-seq Displays Immunomodulatory Effects on Human Macrophages and Anti-Tumor Properties towards In Vitro 2D and 3D Models of Colon Carcinoma and in an In Vivo Subcutaneous Xenograft Colon Carcinoma Model. International Journal of Molecular Sciences, 2022, 23, 6059.	4.1	7
3	Clarifying the molecular mechanism of tomentosin†induced antiproliferative and proapoptotic effects in human multiple myeloma via gene expression profile and genetic interaction network analysis. International Journal of Molecular Medicine, 2021, 48, .	4.0	2
4	Tomentosin a Sesquiterpene Lactone Induces Antiproliferative and Proapoptotic Effects in Human Burkitt Lymphoma by Deregulation of Anti- and Pro-Apoptotic Genes. Life, 2021, 11, 1128.	2.4	4
5	BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 9595.	4.1	25
6	Antiproliferative and proapoptotic effects of <i>Inula viscosa</i> extract on Burkitt lymphoma cell line. Tumor Biology, 2020, 42, 101042831990106.	1.8	15
7	12â€Oâ€tetradecanoylphorbolâ€13â€acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells. Journal of Cellular Physiology, 2018, 233, 2360-2365.	4.1	13
8	A new parameter of growth inhibition for cell proliferation assays. Journal of Cellular Physiology, 2018, 233, 4106-4115.	4.1	7
9	BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC. Oncotarget, 2018, 9, 18734-18746.	1.8	12
10	Design of a Lentiviral Vector for the Inducible Expression of MYC: A New Strategy for Construction Approach. Molecular Biotechnology, 2017, 59, 200-206.	2.4	6
11	<i>MYCL</i> is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells. Oncotarget, 2016, 7, 77378-77388.	1.8	46
12	Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation. Oncotarget, 2016, 7, 31014-31028.	1.8	51
13	On the role of retinoblastoma family proteins in the establishment and maintenance of the epigenetic landscape. Journal of Cellular Physiology, 2013, 228, 276-284.	4.1	24
14	Correction: CTCF and BORIS Regulate $Rb2/p130$ Gene Transcription: A Novel Mechanism and a New Paradigm for Understanding the Biology of Lung Cancer. Molecular Cancer Research, 2013, 11, 1292-1292.	3.4	0
15	The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation. Cell Cycle, 2012, 11, 3828-3836.	2.6	47
16	The tumor suppressor role of CTCF. Journal of Cellular Physiology, 2012, 227, 479-492.	4.1	44
17	Human papillomavirus infection in couples undergoing in vitro fertilization procedures: impact on reproductive outcomes. Fertility and Sterility, 2011, 95, 1845-1848.	1.0	110
18	CTCF and BORIS Regulate <i>Rb2/p130</i> Gene Transcription: A Novel Mechanism and a New Paradigm for Understanding the Biology of Lung Cancer. Molecular Cancer Research, 2011, 9, 225-233.	3.4	39

#	Article	IF	CITATIONS
19	Senescence and p130/Rbl2: a new beginning to the end. Cell Research, 2009, 19, 1044-1051.	12.0	39
20	The role of Aurora-A inhibitors in cancer therapy. Annals of Oncology, 2007, 18, vi47-vi52.	1.2	50